

**An open letter to the Australian Huntington's community from the Huntington's Disease Network of Australia (HDNA) following the 20 November 2024 press release from Sage Therapeutics:**

On 20<sup>th</sup> November 2024, Sage Therapeutics issued a press release regarding the outcome of their completed Phase 2 DIMENSION trial. The key information from the press release is that although the study drug, dalzanemdor is generally safe and well tolerated, it does not improve people with Huntington's disease' (HD) ability to think, learn and remember information.

As a result of these findings, Sage Therapeutics have decided to discontinue their Phase 3 PURVIEW trial which was assessing the long-term safety and tolerability of dalzanemdor in a larger group of people with HD.

Although this news is disappointing, it is important to remember that a lot of important information has been gained through these two trials which will be used to inform future HD trials and research. We are encouraged by the fact that there are numerous life sciences companies working to rapidly start more potential treatment trials.

We remain hopeful that effective HD treatments are not too far away which will help to improve the quality of life of those affected by HD.

We thank and are grateful to the participants, their families and to the Australian site staff who have all contributed so much of their time and effort to these two Sage trials. Australia continues to make important contributions to finding treatment for HD, with other trials still being conducted globally, including at various Australian sites.

We thank all those who have and are currently participating in and contributing to all types of HD research.

From the Huntington's Disease Network of Australia (HDNA)